

Thubrikar Aortic Valve, Inc.
Our next-gen Transcatheter Aortic Valve Implantation (TAVI) system was designed for durability. It's shown preclinical superiority, and clinical feasibility.
- Stage Prototype Ready
- Industry Medical Devices and Equipment
- Location Norristown, PA, USA
- Currency USD
- Founded October 2010
- Employees 5
- Incorporation Type C-corp
- Website TAVI.us
Company Summary
Dr. Mano Thubrikar designed Optimum TAV after the natural aortic valve for maximum durability. The Company's Brazilian licensee started a clinical trial with our Optimum TAVI System (includes PRECISION delivery catheter) in 2018, and our Chinese licensee will start in 2019. Our licensees will provide ongoing clinical data (and royalties). Preclinical superiority shown (e.g. 24 years in durability test, less pressure gradient in sheep).
Team
-
President, Founder, and Board Director
Dr. Thubrikar is a world-renowned authority on the aortic valve. He previously worked as Director of BME at South Dakota School of Mines and Technology; as Edwards Distinguished Research Scientist at Edwards Lifesciences Corp.; as Director of BME at The Heineman Medical Research Center; and as Director of Surgical Research in the Department of Surgery at UVA. Dr. Thubrikar authored “Vascular Mechanics and Pathology” and “The Aortic Valve”.
-
Co-Founder, Vice President of Business Development
Mr. Wadke leads the strategic operations of the Company with over 20+ years of cross-functional experience. Prior to the Company, he consulted for early-stage pharmaceutical companies. From 2007-2009, he worked for VGX Pharma in Business Development, including its integration of an acquisition and its merger with Inovio BioMedical (NYSEMKT:INO). He previously worked in financial, marketing, and strategy roles at J.P. Morgan and MB Financial.
-
Co-Founder, Counsel and Corporate Secretary
Mr. Heble is a registered patent attorney with significant experience handling intellectual property matters related to a wide range of life science-based technologies. Mr. Heble began his legal career with an Am Law 100 law firm, and most recently held the position of Senior Patent Counsel for a Fortune 500 consumer products company.
-
Co-Founder, Board Director
Dr. Wadke is familiar with contemporary cGMP requirements, including the generation of technical data packages for the U.S. and OUS regulatory filings. In 1994, he retired from BMS after 25 years there, most recently as Director of R&D. Through 2012, he consulted PhRMA, generic and start-up companies globally in product development and regulatory compliance. Dr. Wadke consults part-time for Company.
-
Board Member, Principal Investor
Mr. Parate has over 20 years of entrepreneurial and management experience in the financial industry. He began his career at Susquehanna International Group, and has since co-founded multiple trading firms. He consults part-time for the Company.
-
Board Member, Principal Investor
Dr. Zhu is President and Founder of CCRF, a leading CRO for medical devices focused on interventional cardiology in China. Wide Line Limited is the main shareholder of CCRF. He has over 20 years of medical device experience. He has also co-founded start-up companies for interventional cardiology devices and serves as a Board Member to multiple medical companies. He holds an MBBS and an MBA.
-
Director of Product Development
Mr. Eberhardt has over 25 years of experience in medical device development including over 20 years developing catheter based devices, and over 15 years leading development teams from concept through commercial sale and building the design control systems required. He has produced innovations that resulted in over a dozen patents, and extensive experience collecting physician feedback for product design. He has a B.S. in Mechanical Engineering.
Advisors
-
Susheel KodaliUnconfirmed
Previous Investors
-
TAVI physician, St. Mary's HospitalAngel Investors